1. Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. (2nd April 2018) Authors: Díez‐Campelo, María; Lorenzo, Jose I.; Itzykson, Raphael; Rojas, Silvia M.; Berthon, Céline; Luño, Elisa; Beyne‐Rauzy, Odile; Perez‐Oteyza, Jaime; Vey, Norbert; Bargay, Joan; Park, Sophie; Cedena, Teresa; Bordessoule, Dominique; Muñoz, Juan A.; Gyan, Emmanuel; Such, Esperanza; Visanica, Sorin; Ló... Journal: British journal of haematology Issue: Volume 181:Number 3(2018) Page Start: 350 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Issue 14 (6th December 2019) Authors: Foltz, Lynda; Pica, Gian-Matteo; Zerazhi, Hacene; Van Droogenbroeck, Jan; Visanica, Sorin; Báez de la Fuente, Enrique; Leber, Brian; de Almeida, Antonio Medina; Ranta, Dana; Kiladjian, Jean-Jacques; Chrit, Linda; Kandra, Albert; Morando, Juliane; Devos, Timothy Journal: Leukemia & lymphoma Issue: Volume 60:Issue 14(2019) Page Start: 3493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗